Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.

[1]  Deepak L. Bhatt,et al.  Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. , 2004, The American journal of cardiology.

[2]  Deepak L. Bhatt,et al.  Benefit of Clopidogrel Over Aspirin Is Amplified in Patients With a History of Ischemic Events , 2004, Stroke.

[3]  M. Aarabi,et al.  Aspirin for primary prevention of coronary heart disease. , 2004, The Cochrane database of systematic reviews.

[4]  E. Topol,et al.  Mutation of MEF2A in an Inherited Disorder with Features of Coronary Artery Disease , 2003, Science.

[5]  S. Yusuf,et al.  Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study , 2003, Circulation.

[6]  R. Califf,et al.  Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease , 2003, Circulation.

[7]  Deepak L. Bhatt,et al.  Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions , 2003, Circulation.

[8]  Eric J. Topol,et al.  Scientific and therapeutic advances in antiplatelet therapy , 2003, Nature Reviews Drug Discovery.

[9]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[10]  Deepak L. Bhatt,et al.  Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. , 2002, The American journal of cardiology.

[11]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[12]  Deepak L. Bhatt,et al.  Need to test the arterial inflammation hypothesis. , 2002, Circulation.

[13]  Deepak L. Bhatt,et al.  Early and Sustained Survival Benefit Associated With Statin Therapy at the Time of Percutaneous Coronary Intervention , 2002, Circulation.

[14]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[15]  C. Mulrow,et al.  Aspirin for the Primary Prevention of Cardiovascular Events: A Summary of the Evidence for the U.S. Preventive Services Task Force , 2002, Annals of Internal Medicine.

[16]  U. P. S. T. Force,et al.  Measuring Quality: Are We Ready To Compare the Quality of Care among Physician Groups? , 2002, Annals of Internal Medicine.

[17]  C. Mulrow,et al.  Aspirin for the primary prevention of cardiovascular events , 2002 .

[18]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[19]  Deepak L. Bhatt,et al.  Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. , 2002, Journal of the American College of Cardiology.

[20]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[21]  S. Yusuf,et al.  Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. , 2001, Circulation.

[22]  Deepak L. Bhatt,et al.  Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting. , 2001, The Journal of invasive cardiology.

[23]  S. Yusuf,et al.  Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. , 2001, Circulation.

[24]  M Freedman,et al.  Single Nucleotide Polymorphisms in Multiple Novel Thrombospondin Genes May Be Associated With Familial Premature Myocardial Infarction , 2001, Circulation.

[25]  Deepak L. Bhatt,et al.  Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. , 2001, The American journal of cardiology.

[26]  Salim Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.

[27]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[28]  P. Ghahramani,et al.  Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials , 2001, Heart.

[29]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[30]  Deepak L. Bhatt,et al.  Superiority of Clopidogrel Versus Aspirin in Patients With Prior Cardiac Surgery , 2001, Circulation.

[31]  K. Schrör,et al.  Platelet CD40 ligand (CD40L) – subcellular localization, regulation of expression, and inhibition by clopidogrel , 2001, Platelets.

[32]  Deepak L. Bhatt,et al.  Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease. , 2001, The Medical clinics of North America.

[33]  P Glasziou,et al.  Pravastatin therapy and the risk of stroke. , 2000, The New England journal of medicine.

[34]  Deepak L. Bhatt,et al.  Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. , 2000, American heart journal.

[35]  Deepak L. Bhatt,et al.  Update on Clinical Trials of Antiplatelet Therapy for Cerebrovascular Diseases , 2000, Cerebrovascular Diseases.

[36]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[37]  Philip Greenland,et al.  Prevention Conference V Beyond Secondary Prevention : Identifying the High-Risk Patient for Primary Prevention : Executive Summary , 2000 .

[38]  V. Fuster,et al.  Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. , 2000, Circulation.

[39]  J. Larosa,et al.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.

[40]  R Brian Haynes,et al.  Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial , 1999, The Lancet.

[41]  S. Pocock,et al.  A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting , 1998 .

[42]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[43]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[44]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[45]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[46]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[47]  A. Algra,et al.  A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. , 1991, The New England journal of medicine.

[48]  A. Jaffe,et al.  Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase , 1988 .

[49]  A. Jaffe,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. , 1988, Journal of the American College of Cardiology.